NO20044041L - Oxo-azabicyclic compounds - Google Patents
Oxo-azabicyclic compoundsInfo
- Publication number
- NO20044041L NO20044041L NO20044041A NO20044041A NO20044041L NO 20044041 L NO20044041 L NO 20044041L NO 20044041 A NO20044041 A NO 20044041A NO 20044041 A NO20044041 A NO 20044041A NO 20044041 L NO20044041 L NO 20044041L
- Authority
- NO
- Norway
- Prior art keywords
- integer
- formula
- group
- nalkyl
- rer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Forbindelse valgt fra slike med formel (I) hvori: X,, Xog Xrepresenterer ftxtef^-CRi hvilken Ra er som beskrevet i beskrivelsen, Gi representerer en gnjjj§4g|^ fra slike ifølge formlene (i/a) og (i/b) i hvilke R, Rs og Rer som definert i'" """"" beskrivelsen, G2 representerer en gruppe valgt fra karbon-karbon trippelbinding, - CH=C=CH-, C=0, C=S, S(0)i hvilke n1 representerer et helt tall fra 0 til og med 2, eller en gruppe ifølge formelen (i/c) i hvilken Yrepresenterer O, S, -NH eller. -Nalkyl, og Yrepresenterer O, S, -NH eller -Nalkyl, ri er et helt tall fra 0 til og med 6, og m er et helt tall f ra 0 til og med 7, Zrepresenterer -CRgR, hvori Rg og Rer som definert i beskrivelsen, A representerer et ringsystem, Ri representerer en gruppe valgt fra H, alkyl, alkenyl, alkynyl, eventuelt substituert og gruppen med formel (i/d) i hvilken p, Z, B, q og Ger som definert i beskrivelsen og eventuelt, dens optiske isomerer, N-oksyd, og addisjonssalter derav med en farmasøytisk akseptabel syre eller base, og medisinske produkter inneholdende samme er nyttige som spesifikke inhibitorer for typa-13 matriks metalloprotease.A compound selected from those of formula (I) wherein: X 1, X 1 and X 1 represent x ) in which R, Rs and Rer as defined in the "" "" "" description, G2 represent a group selected from carbon-carbon triple bond, - CH = C = CH-, C = 0, C = S, S (0 ) in which n1 represents an integer from 0 to 2, or a group according to the formula (i / c) in which Y represents O, S, -NH or. -Nalkyl, and Y represents O, S, -NH or -Nalkyl, ri is an integer from 0 to 6, and m is an integer from 0 to 7, represents -CRgR, wherein Rg and Rer as defined in the specification, A represents a ring system, R 1 represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i / d) in which p, Z, B, q and Ger as defined in the specification and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type 13 matrix metalloprotease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/003240 WO2003076416A1 (en) | 2002-03-08 | 2002-03-08 | Oxo azabicyclic compounds |
| PCT/EP2003/002277 WO2003076417A2 (en) | 2002-03-08 | 2003-03-06 | Oxo-azabicyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20044041L true NO20044041L (en) | 2004-10-07 |
Family
ID=27798761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044041A NO20044041L (en) | 2002-03-08 | 2004-09-24 | Oxo-azabicyclic compounds |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1492775A2 (en) |
| JP (1) | JP2005526070A (en) |
| KR (1) | KR20040095270A (en) |
| CN (1) | CN1738806A (en) |
| AP (1) | AP2004003125A0 (en) |
| AR (1) | AR039562A1 (en) |
| AU (2) | AU2002249275A1 (en) |
| BR (1) | BR0308280A (en) |
| CA (1) | CA2478706A1 (en) |
| CO (1) | CO5601020A2 (en) |
| EA (1) | EA200401053A1 (en) |
| EC (1) | ECSP045278A (en) |
| IL (1) | IL163818A0 (en) |
| IS (1) | IS7414A (en) |
| MA (1) | MA27183A1 (en) |
| MX (1) | MXPA04008681A (en) |
| NO (1) | NO20044041L (en) |
| OA (1) | OA12782A (en) |
| PA (1) | PA8568501A1 (en) |
| PE (1) | PE20031018A1 (en) |
| PL (1) | PL372622A1 (en) |
| SV (1) | SV2003001495A (en) |
| TN (1) | TNSN04169A1 (en) |
| UY (1) | UY27700A1 (en) |
| WO (2) | WO2003076416A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | TRIAZOLO COMPOUNDS AS MMP INHIBITORS |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| JP2006501215A (en) | 2002-08-13 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| WO2004014868A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| MXPA05001785A (en) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Chromone derivatives as matrix metalloproteinase inhibitors. |
| WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| MXPA05001786A (en) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors. |
| PA8578101A1 (en) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
| ES2389907T3 (en) * | 2004-04-30 | 2012-11-02 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an MMP-13 inhibitor |
| KR20070028536A (en) * | 2004-06-15 | 2007-03-12 | 아스트라제네카 아베 | Substituted quinazolones as anti-cancer agents |
| CA2665476A1 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| CN103524431B (en) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-benzyl-4-quianzolinones and synthetic method thereof and application |
| JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
| HUE057090T2 (en) | 2015-09-23 | 2022-04-28 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| DK3353177T3 (en) | 2015-09-23 | 2020-08-24 | Janssen Pharmaceutica Nv | TRICYCLIC HETEROCYCLES FOR CANCER TREATMENT |
| FR3046793B1 (en) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0946095A1 (en) * | 1996-12-17 | 1999-10-06 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| PA8539301A1 (en) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX |
| PA8539401A1 (en) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | QUINAZOLINAS AS INHIBITORS OF MMP-13 |
-
2002
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/en not_active Application Discontinuation
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/en not_active Application Discontinuation
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/en not_active Application Discontinuation
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/en unknown
- 2003-03-06 CA CA002478706A patent/CA2478706A1/en not_active Abandoned
- 2003-03-06 IL IL16381803A patent/IL163818A0/en unknown
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/en not_active Application Discontinuation
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/en not_active Withdrawn
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 EA EA200401053A patent/EA200401053A1/en unknown
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/en unknown
- 2003-03-06 CN CNA038048752A patent/CN1738806A/en active Pending
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/en not_active Application Discontinuation
- 2003-03-06 AR ARP030100749A patent/AR039562A1/en not_active Application Discontinuation
- 2003-03-06 PL PL03372622A patent/PL372622A1/en not_active Application Discontinuation
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/en not_active IP Right Cessation
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 UY UY27700A patent/UY27700A1/en not_active Application Discontinuation
- 2003-03-06 EP EP03708181A patent/EP1492775A2/en not_active Withdrawn
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/en unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/en not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/en unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/en unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/en unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04008681A (en) | 2004-12-06 |
| JP2005526070A (en) | 2005-09-02 |
| MA27183A1 (en) | 2005-01-03 |
| EP1492775A2 (en) | 2005-01-05 |
| BR0308280A (en) | 2004-12-28 |
| WO2003076417A2 (en) | 2003-09-18 |
| TNSN04169A1 (en) | 2007-03-12 |
| PL372622A1 (en) | 2005-07-25 |
| IS7414A (en) | 2004-08-19 |
| CO5601020A2 (en) | 2006-01-31 |
| KR20040095270A (en) | 2004-11-12 |
| AP2004003125A0 (en) | 2004-09-30 |
| PE20031018A1 (en) | 2004-01-09 |
| AR039562A1 (en) | 2005-02-23 |
| CN1738806A (en) | 2006-02-22 |
| ECSP045278A (en) | 2004-10-26 |
| EA200401053A1 (en) | 2005-04-28 |
| CA2478706A1 (en) | 2003-09-18 |
| IL163818A0 (en) | 2005-12-18 |
| PA8568501A1 (en) | 2003-12-19 |
| AU2002249275A1 (en) | 2003-09-22 |
| OA12782A (en) | 2006-07-10 |
| WO2003076417A3 (en) | 2003-11-13 |
| UY27700A1 (en) | 2003-10-31 |
| SV2003001495A (en) | 2003-11-04 |
| AU2003212307A1 (en) | 2003-09-22 |
| WO2003076416A1 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20044041L (en) | Oxo-azabicyclic compounds | |
| NO20025719D0 (en) | Novel triazole pyrimidine compounds | |
| NO20066055L (en) | pyridine derivatives | |
| NO20091858L (en) | Hydrobenzamide derivatives as inhibitors of HSP90 | |
| JO2646B1 (en) | Novel heterocyclic compounds which are active as inhibitors of beta-lactamases | |
| DK1585739T3 (en) | Substituted arylcyclopropylacetamides as glucokinase activators | |
| NO20055977L (en) | New benzimidazole derivatives | |
| HUP0203385A2 (en) | Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0300370A2 (en) | 2-hydroxy-mutilin carbamate derivatives of antibacterial effect process for preparation and pharmaceutical compositions containing them | |
| DE122005000041I2 (en) | Nucleotide analogs. | |
| DE50113943D1 (en) | 4-ALKOXY-CYCLOHEXAN-1-AMINO-CARBOXYLIC ACID ESTERS AND METHOD FOR THE PRODUCTION THEREOF | |
| AU8811401A (en) | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | |
| DK0752854T3 (en) | Pyrimidine or triazine carboxylic acid derivatives for use as a drug | |
| NO20063111L (en) | Process for the preparation of thiazole pyrimidines | |
| EA200500133A1 (en) | PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF OXYTOCIN | |
| MX2007006744A (en) | Hydantoin derivatives useful as metalloproteinase inhibitors. | |
| EP1027051A4 (en) | Antithrombotic agents | |
| ATE258934T1 (en) | AZAINDOLE DERIVATIVES AND THEIR USE AS ANTITHRBOTIC AGENTS | |
| UY26251A1 (en) | CRYSTALLINE FORM III OF N- (4- (5- DIMETILAMINONAFTALEN-1- SULFONILAMINO) FENIL) -3 - HIDROXI-2, 2- DIMETILPROPIONAMIDA | |
| DE60008430D1 (en) | ANTITHROMBOTIC EFFECT COMPOUNDS | |
| EA200100344A2 (en) | New cyclobutaindolecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them | |
| EP1403260A3 (en) | Optically active epoxy compounds and processes for their production | |
| NO20052413L (en) | Substituted aralkyl derivatives | |
| NO20022690D0 (en) | New structural analogues of Vitamin D | |
| ATE268768T1 (en) | ANTITHROMBOTIC AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |